It has been reported that wild type 53 melanoma cells demonstrate enhanced growth suppression in response to Nutlin-3, suggesting p53 status as a potential biomarker identifying tumors responsive to p53-reactivation therapy [48]. The gene discussed is TP53; the disease is melanoma.